Previous studies have shown that EGFR‐TKI combined with an antiangiogenic drug (bevacizumab) is effective in the treatment of advanced NSCLC, and can improve patient survival.9, 10, 11, 12 The clinical study of bevacizumab combined with erlotinib in EGFR‐TKI resistance has also made breakthroughs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.